CytomX Therapeutics (CTMX) Consolidated Net Income (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Consolidated Net Income came in at -$18.2 million in Q1 2026, down 177.57% YoY from $23.5 million in Q1 2025, and up 19.52% on a QoQ basis from -$22.7 million in Q4 2025.
CytomX Therapeutics (CTMX) Consolidated Net Income (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Consolidated Net Income data on file, last reported at -$18.2 million in Q1 2026.
- Quarterly Consolidated Net Income fell 177.57% year-over-year to -$18.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$55.3 million (down 232.94% YoY) and the FY2025 annual result came in at -$13.5 million, down 142.46% from the prior year.
- Consolidated Net Income improved to -$18.2 million in Q1 2026, from -$22.7 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $23.5 million in Q1 2025 to a low of -$32.0 million in Q1 2022.
- A 5-year average of -$5.9 million and a median of -$3.3 million in 2023 frame the typical range for Consolidated Net Income.
- The widest YoY moves for Consolidated Net Income: up 2155.2% in 2024, down 501.1% in 2024.
- Tracing CTMX's Consolidated Net Income over 5 years: stood at -$8.8 million in 2022, then soared by 109.54% to $837000.0 in 2023, then jumped by 2155.2% to $18.9 million in 2024, then tumbled by 220.12% to -$22.7 million in 2025, then increased by 19.52% to -$18.2 million in 2026.
- The last three Consolidated Net Income figures came in at -$18.2 million (Q1 2026), -$22.7 million (Q4 2025), and -$14.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | -20.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.67 Mn |
| Mar 31, 2026 | -18.25 Mn |
| Dec 31, 2025 | -22.67 Mn |
| Sep 30, 2025 | -14.23 Mn |
| Jun 30, 2025 | -154,000.00 |
| Mar 31, 2025 | 23.53 Mn |
| Dec 31, 2024 | 18.88 Mn |
| Sep 30, 2024 | 5.74 Mn |
| Jun 30, 2024 | -6.53 Mn |
| Mar 31, 2024 | 13.79 Mn |
| Dec 31, 2023 | 837,000.00 |
| Sep 30, 2023 | 2.99 Mn |
| Jun 30, 2023 | -1.09 Mn |
| Mar 31, 2023 | -3.31 Mn |
| Dec 31, 2022 | -8.78 Mn |
| Sep 30, 2022 | -29.06 Mn |
| Jun 30, 2022 | -29.50 Mn |
| Mar 31, 2022 | -31.98 Mn |
| Dec 31, 2021 | -34.82 Mn |
| Sep 30, 2021 | -30.98 Mn |